As reported, about 3 years post implant of the bard/davol ventralight st mesh using echo ps, the patient was diagnosed with hernia recurrence.As reported, the ae has not resolved and the patient has been advised to lose weight before a surgery could be performed.The clinician has assessed the patient¿s postoperative course as being ¿possibly¿ related to the study device and to the procedure, however, based on the information provided, no conclusion can be made.Hernia recurrence is a known inherent risk of hernia repair surgery.The adverse reactions section of the instructions-for-use, supplied with the device lists hernia recurrence as a possible complication.Review of manufacturing records confirms product was manufactured to specification.This mdr represents the adverse event of hernia recurrence.An additional mdr was submitted to represent the adverse event of seroma.Device not returned - remains implanted.
|
Reported per clinical trial dvl-he-020: on 03-jun-2014- subject patient underwent robotic assisted incisional hernia repair procedure.A bard/davol ventralight st was implanted using echo ps and fixated with bard/davol sorbafix fixation device and sutures.The size of the hernia defect was 30cm.Full skin closure was achieved using adhesive skin closure.On 08-jul-2017- subject patient presented to emergency department with abdominal pain and the patient's ct scan revealed ventral incisional recurrent hernia.As reported, the surgeon advised the patient that a surgery could not be performed until the bmi reduces to <50.As reported, the patient had not returned yet.Per the study clinician, the reported adverse event has been assessed as severe in severity, possibly related to the study device and possibly related to the index procedure.The outcome for this ae is reported has not recovered/not resolved.
|